TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Contraction of pelvic floor muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Likelihood ratio of the galactomannan assay to return a positive result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood ratio of fungal PCRs to return a positive result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood ratio of cell-free next generation DNA/RNA sequencing identifying a fungal pathogen to return a positive result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood ratio of molecular RNAseq platform assessing host immune response to return a positive result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TIGAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRIM59
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Schirmer I Test (Without Anesthesia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target volume CTV-HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of Posttraumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to first opioid administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Caries status (dmfs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child linear growth status at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of cigarettes a day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST-segment resolution immediately after primary angioplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Blush grade after angioplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of severe critical events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokines concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GABA concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Resection Rate (R0-resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of subjects with treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with localized administration site AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of subjects with localized administration site AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with VL<1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale for pain intensity (VASPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidermal Nerve Fiber Density (ENFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Epidermal Nerve Fiber Density Regeneration (ENFDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of completed post discharge visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tremor and Coordination Scale (TACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from baseline in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in bacterial load of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in bacterial biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appointment Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood Culture Contamination Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes of pain scores (VRS) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of pain scores (VRS) at motion activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-averaged change in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in abdominal Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eMurmur ID sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression Levels of Antimicrobial Peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of Innate Immune Genes (IL6, IL8, IL1B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients Who Were Intubated
Endpoint domain: Adverse events/effects
Primary endpoint: Static and dynamic postural sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Train Of Four Ratio (TOFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MI (non fatal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke (non fatal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HBV Reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Glomerular filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time before the first morbi-mortality event
Endpoint domain: Mortality/survival
Primary endpoint: Post Traumatic Stress Disorder Symptoms/Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With at Least One Treatment-emergent Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Withdrew From the Study Due to a Treatment-emergent Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean differences in hyaline cartilage biochemical composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in morphological joint abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain due to menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose-lowering potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deterioration in Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Management of neonatal sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Lung Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: daily drainage volume during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total drainage volume during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-drain removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Geometric mean titer measured by Enzyme-linked Immunosorbent Assay(ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate measured by Enzyme-linked Immunosorbent Assay(ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of Solicited Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Over Active Bladder questionnaire Short Form (OAB-q SF) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient assessment of treatment satisfaction (TS-VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual status at conclusion of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache status at conclusion of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected farsight visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by clinical monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritonitis related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive Complication Index (CCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change of awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change of concern and knowledge acquisition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percent change of motivation and attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent change of behavior adoption
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Placeability and comfort of the device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage changes in ApoB/ApoA-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Receiver Operating Curve (AUC of ROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid Plaque Burden Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical perioperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of the Straight Leg Raising test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in tremor-stimulation phase entrainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Micronutrient Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aberrant Behavior Checklist (ABC) subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post Traumatic Stress Disorder Symptom Severity - Clinician Rated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Traumatic Stress Disorder Symptom Severity - Self Report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syndecan 4 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence of SARS-Cov-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in levels of SARS-Cov-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Numbers of infected patients
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with syncope recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean percent change in non-inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection of colorectal lung metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Who Experienced Severe TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Withdraw Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Trails A and B task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: The Recovery Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average percentage of double positive T cells CD4 + / CD8 +
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of urinary incontinence based on 24-hour pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total Exercise Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measurement Bias of Calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement Bias of Lipid-rich Necrotic Core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow-mediated Dilation of the Brachial Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of SB1518
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Aerobic activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Step counts
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: shortening length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cost of Erythropoiesis Stimulating Agent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PBR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite quality score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: composite high risk score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of Postoperative Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulatory Homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC INS-GLR 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC GIR 0-24hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Related quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Clinical Chemistry Parameters by Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in hip bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieve Clinical Response at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of adenoma and colorectal cancer (CRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rosenberg Self-Esteem (R-SES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptom Checklist 90-R (SCL90-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day 7 Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Initiation of breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Sustainment of exclusive breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Difference in rates of sustainment of exclusive breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Nonalcoholic Steatohepatitis (NASH) Patients With Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Transaminase Levels (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Aspartate Transaminase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in % of Fat in the Liver Assessed Using Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Overall cough count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator rated overall procedure satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV)
Endpoint domain: Adverse events/effects
Primary endpoint: A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Failure to achieve the area under the curve (AUC) target range despite dose adjustment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intrapleural pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes of Tiselius Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes of urinary oxalate level (mmol/24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of Imaging Modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Disease-free Patients
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in bowel habits and related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with R0 resection after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Exposure Adjusted Incidence Rates of AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment persistence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Peabody Developmental Motor Scales 2 (PDMS-2) test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gesell developmental scale test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Blood Flow Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Food intake at an ad libitum buffet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activity in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucagon responses (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCt of CKD-348
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-348
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) <21mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dimensional changes of the alveolar crest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to discharge home
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maternal or Perinatal death or morbidity
Endpoint domain: Mortality/survival